Immunoflazid syrup
Producer: LLC NPK Ekofarm Ukraine
Code of automatic telephone exchange: L03AX
Release form: Liquid dosage forms. Syrup.
General characteristics. Structure:
Active ingredients: 100 ml of syrup contain Proteflazid® – liquid эстракт (1:1), Shchuchki received from mix of a grass turfy (Herba Deschampsia caespitosa L.) and herbs of the Smallreed land (Herba Calamagrostis epigeios L.), which contains not less than 0,32 mg of flavonoids in terms of Rutinum and not less than 0,3 mg of the sum of carboxylic acids in terms of malic acid;
excipients: propylene glycol, ethanol of 96%, sorbite (Е 420), methylparaben (Е 218), propylparaben (Е 216), sodium sulfite (Е 221), the water purified.
Pharmacological properties:
The flavonoids which are a part of drug have ability to suppress DNA replication and RNA of viruses both in vitro, and in vivo. When performing preclinical and clinical trials it is revealed the inhibiting activity of drug concerning viruses of acute respiratory infections, viruses of herpes of all types.
The mechanism of antiviral action consists in inhibition of virusospetsifichesky enzymes of a DNA polymerase, thymidinekinase and the return transcriptase.
The mechanism of direct anti-influenzal effect of drug consists in inhibition of neyraminidazny activity, induction of synthesis of endogenous interferon, a RNA synthesis ingibition.
Drug protects mucous membranes of upper respiratory tracts, normalizing indicators of local immunity due to increase in level of lactoferrin and sIgA.
During the researches it is established that drug normalizes synthesis of endogenous a-and g-of interferon, to physiologically active level that increases nonspecific resistance of an organism to a viral and bacterial infection. By clinical trials it is established that in the conditions of long-term daily use of drug there is no refrakternost of immune system: oppression of activity of a-and g-of interferon is not observed thanks to what the immune status of the person is normalized. It gives the chance to use drug for a long time for treatment of recurrent persistent infections.
Single oral administration leads to active synthesis of interferon up to 6 days with the peak of concentration on second day.
Drug has antioxidant activity as interferes with accumulation of products of peroxide oxidation of lipids, inhibits the course of free radical processes, thereby strengthening the antioxidant status of cells, reduces intoxication, promotes recovery of an organism after the postponed infection and adaptation to unfavorable environmental conditions.
Drug is the apoptosis modulator, strengthening effect of apoptozindutsiruyushchy substances that promotes more bystry elimination of the cells affected with a virus and prevention of developing of chronic diseases against the background of latent viral infections.
Indications to use:
-
Prevention and treatment of a SARS;
-
prevention and treatment of flu, including pandemic strains;
-
for the purpose of normalization of indicators of immune system at acute and persistent viral infections.
Route of administration and doses:
To dose drug by means of the dosing capacity and to accept in 20-30 minutes prior to food.
Before the use drug needs to be shaken up.
Doses and duration of treatment depend on the nature of a disease and age of the patient (see tab. 1).
| Children from the birth about one year | on 0,5 ml 2 times a day for 14 days. |
| Children from 1 to 2 years | on 1 ml 2 times a day for 14 days. |
| Children age from 2 to 4 years | from the 1st on 3y day on 1,5 ml 2 times a day; from the 4th day on 3 ml 2 times a day for 14 days. |
| Children age from 4 to 6 years | from the 1st on 3y day on 3 ml 2 times a day; from the 4th day on 4 ml 2 times a day for 14 days. |
| Children age from 6 to 9 years | from the 1st on 3y day on 4 ml 2 times a day; from the 4th day on 5 ml 2 times a day for 14 days. |
| Children age from 9 to 12 years | from the 1st on 3y day on 5 ml 2 times a day; from the 4th day on 6 ml 2 times a day for 14 days. |
| Children age are more senior than 12 years and adults | from the 1st on 3y day on 5 ml 2 times a day; from the 4th day on 8 ml 2 times a day for 14 days. |
la of treatment of flu and SARS use drug within 2 weeks.
For prevention of flu and a SARS drug is used by from 2 to 4 weeks.
During epidemic of a pandemic strain the term of use of drug can be prolonged to
6 weeks.
In case of bacterial complications of flu and other SARS for the purpose of normalization of indicators of immune system drug is used within 4 weeks.
For the purpose of normalization of indicators of immune system at acute and persistent viral infections administration of drug continues from 12 to 26 weeks.
Features of use:
Use during pregnancy or feeding by a breast.
Иммунофлазид® apply to children.
Ability to influence speed of response at control of motor transport or work with other mechanisms.
Negative influence on carrying out potentially dangerous types of activity requiring special attention and bystry reaction is not revealed.
Children.
Иммунофлазид® apply to children from the birth.
Side effects:
Drug use, as a rule, does not cause side effects. Isolated cases of gastrointestinal frustration – pain in epigastric area, nausea, vomiting, diarrhea (in the presence of these symptoms it is necessary to accept drug in 1,5-2 hours after food) were observed. Perhaps tranzitorny fervescence to 38 °C for the 3-10th day of therapy by drug.
At patients with a chronic gastroduodenit the aggravation of a gastroduodenit, emergence of a gastroesophageal reflux is possible (reflux esophagitis).
Allergic reactions develop seldom, mainly in the form of erythematic rashes.
The headache is in rare instances possible. These phenomena disappeared after dose adjustment and the mode of administration of drug.
Interaction with other medicines:
During a clinical use an opportunity and expediency of a combination of Immunoflazida® with antibiotics and antifungal drugs for treatment virus and bacterial and virus fungus diseases is established. Negative manifestations owing to interaction with other medicines it is not established.
Contraindications:
Hypersensitivity to drug components. A peptic ulcer of a stomach or duodenum in an aggravation stage. Autoimmune diseases.
Appropriate security measures at use.
Patients with a chronic gastroduodenit, in case of an aggravation of a gastroduodenit, at emergence of a gastroesophageal reflux need to accept drug in 1,5-2 hours after food. At tranzitorny fervescence to 38 °C it is necessary temporarily , to reduce for 2-3 days a dose of Immunoflazida® twice.
Overdose:
Cases of overdose are unknown, but development of side effects is possible, especially from digestive tract.
Symptomatic treatment.
Storage conditions:
Period of validity - 2 years.
Not to apply after the period of validity specified on packaging.
To store in protected from light and the place, unavailable to children, at a temperature up to 25 ˚С.
Not to freeze!
After the first opening of a container to store it closed in the place protected from light no more than 30 days.
Issue conditions:
Without recipe
Packaging:
On 50 ml or 125 ml in bottles from dark glass or plastic. The dosing capacity invests in packaging.
